Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Garassino MC, et al. Among authors: chouaid c. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12. Lancet Oncol. 2018. PMID: 29545095 Free PMC article. Clinical Trial.
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Pérol M, et al. Among authors: chouaid c. J Clin Oncol. 2012 Oct 1;30(28):3516-24. doi: 10.1200/JCO.2011.39.9782. Epub 2012 Sep 4. J Clin Oncol. 2012. PMID: 22949150 Clinical Trial.
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Mazières J, et al. Among authors: chouaid c. J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610105
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).
Rittmeyer A, Gorbunova V, Vikström A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F. Rittmeyer A, et al. Among authors: chouaid c. J Thorac Oncol. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf. J Thorac Oncol. 2013. PMID: 24077452 Free article. Clinical Trial.
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. Scagliotti GV, et al. Among authors: chouaid c. J Thorac Oncol. 2013 Dec;8(12):1529-37. doi: 10.1097/JTO.0000000000000005. J Thorac Oncol. 2013. PMID: 24389434 Free article. Clinical Trial.
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer.
Lerouge D, Rivière A, Dansin E, Chouaid C, Dujon C, Schott R, Lavole A, Le Pennec V, Fabre E, Crequit J, Martin F, Dehette S, Fournel P, Precheur-Agulhon B, Lartigau E, Zalcman G. Lerouge D, et al. Among authors: chouaid c. BMC Cancer. 2014 Mar 30;14:231. doi: 10.1186/1471-2407-14-231. BMC Cancer. 2014. PMID: 24678902 Free PMC article. Clinical Trial.
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, Fraboulet G, Locher C, Le Treut J, Hominal S, Vergnenegre A. Chouaid C, et al. Lung Cancer. 2014 Nov;86(2):170-3. doi: 10.1016/j.lungcan.2014.08.016. Epub 2014 Aug 29. Lung Cancer. 2014. PMID: 25214431
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C; IFCT-GFPC investigators. Borget I, et al. Among authors: chouaid c. BMC Cancer. 2014 Dec 15;14:953. doi: 10.1186/1471-2407-14-953. BMC Cancer. 2014. PMID: 25511923 Free PMC article. Clinical Trial.
406 results